Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous FMT for Preventing Acute GVHD After Haplo-HSCT
NCT04745221Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of autologous fecal microbiota transplantation in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Cumulative incidence of grade II-IV acute graft-versus-host disease at 100 days. Started Aug 2021; status: completed.
02
Drugs
autologous fecal microbiota transplantation
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04745221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745221.